Cardiovascular (CV) outcome trials have shown that sodium–glucose cotransporter 2 (SGLT2) inhibitors provide both cardiac and renal protection, leading to significant changes in T2D treatment guidelines. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.